Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.19 - $49.72 $564,303 - $681,164
13,700 Added 49.82%
41,200 $1.83 Million
Q2 2024

Aug 14, 2024

SELL
$27.55 - $48.83 $551,000 - $976,600
-20,000 Reduced 42.11%
27,500 $1.19 Million
Q1 2024

May 15, 2024

BUY
$21.32 - $34.81 $1.01 Million - $1.65 Million
47,500 New
47,500 $1.39 Million
Q2 2023

Aug 14, 2023

SELL
$21.38 - $29.19 $427,600 - $583,800
-20,000 Reduced 25.0%
60,000 $1.7 Million
Q1 2023

May 15, 2023

BUY
$21.74 - $30.93 $1.09 Million - $1.55 Million
50,000 Added 166.67%
80,000 $1.84 Million
Q3 2022

Nov 14, 2022

BUY
$19.51 - $34.14 $585,300 - $1.02 Million
30,000 New
30,000 $848,000
Q2 2022

Aug 15, 2022

SELL
$17.06 - $31.42 $1.32 Million - $2.44 Million
-77,500 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$26.68 - $34.81 $1.33 Million - $1.74 Million
50,000 Added 181.82%
77,500 $2.26 Million
Q4 2021

Feb 11, 2022

BUY
$29.58 - $49.78 $813,450 - $1.37 Million
27,500 New
27,500 $905,000
Q3 2021

Nov 12, 2021

SELL
$41.92 - $58.18 $2.1 Million - $2.91 Million
-50,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$52.06 - $61.27 $1.3 Million - $1.53 Million
25,000 Added 100.0%
50,000 $2.76 Million
Q3 2020

Nov 16, 2020

SELL
$33.87 - $55.93 $169,350 - $279,650
-5,000 Reduced 16.67%
25,000 $875,000
Q2 2020

Aug 14, 2020

BUY
$34.45 - $53.48 $516,750 - $802,200
15,000 Added 100.0%
30,000 $1.61 Million
Q4 2019

Feb 13, 2020

SELL
$30.08 - $50.59 $451,200 - $758,850
-15,000 Reduced 50.0%
15,000 $716,000
Q3 2019

Nov 14, 2019

BUY
$32.4 - $49.58 $972,000 - $1.49 Million
30,000 New
30,000 $971,000

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $3.05B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.